Biopharma organizations are investing more than ever in patient advocacy, but traditional methods to measure impact through reach, activity, and engagement alone no longer provide the complete picture.

Many are adopting outcomes-focused approaches that demonstrate how patient advocacy contributes to clinical development, market access, commercial objectives, and long-term patient relationships.

Drawing on insights from countless engagements with advocacy teams across industry, our white paper explores how advocacy impact measures can evolve alongside product maturity, market dynamics, and patient advocacy group relationships, moving beyond static key performance indicators to demonstrate real value.

Through real-world case studies, we demonstrate how advocacy efforts connect to outcomes such as clinical trial recruitment, access, and long-term trust.

The white paper also includes Envision’s Adaptive Advocacy Impact Framework, a flexible, scalable approach designed to help teams align across functions, adapt measurement priorities over time, and focus on what matters most.